Pustular Psoriasis After Dupilumab: A Case Report and Systematic Review
Main Article Content
Keywords
dupilumab, psoriasis, pustular, drug-induced
Abstract
Dupilumab is a human monoclonal antibody targeting the interleukin-4 receptor alpha subunit, inhibiting type-2 inflammatory responses through its dual blockade of interleukin-4 (IL-4) and IL-13 signaling. Dupilumab is approved for the treatment of moderate to severe atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyposis. However, recent reports have documented the emergence of pustular psoriasis (PP) during treatment of AD with dupilumab. Whether dupilumab causes pustular psoriasis or merely renders its presentation in patients misdiagnosed with AD remains unclear. By presenting this case and conducting a systematic review, we aim to contribute to the understanding of the potential association between dupilumab therapy and the development of pustular psoriasis. This knowledge will help clinicians in accurately diagnosing and managing patients who develop pustular psoriasis while on dupilumab.
References
2. Xinrui Jia CLJWQL. Pustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatiti. J Drugs Dermatol. 2022;21(3):311-312.
3. Zhong X, Li Y, Gao Y, et al. Pustular psoriasis appearing in a Chinese woman treated with dupilumab for atopic dermatitis: A case report. Dermatol Ther. 2022;35(11). doi:10.1111/dth.15851
4. Incel Uysal P, Gunhan O. De novo pustular psoriasis associated with dupilumab therapy in a young male with the diagnosis of atopic dermatitis. Dermatol Ther. 2022;35(5). doi:10.1111/dth.15399
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.